Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


User Fee Goal Dates

Executive Summary

Estimated FDA review deadlines for pending applications. Updated weekly.


Related Content

Shutdown Week Four: FDA Maintains Pre-Shutdown Output Pace In Some Cases
Sage's Postpartum Depression Drug Brexanolone Faces Loss-Of-Consciousness Questions
US FDA Eliminating 'Sub-Indications' From Inflammatory Bowel Disease Labels
Xeljanz's UC Indication On Track With Higher Doses After Unanimous Advisory Committee Votes
Pfizer Xeljanz's Long-term Dosing Raises Safety Concerns In Ulcerative Colitis
Oral Testosterone Therapy Jatenzo Faces CV, Sampling Tube Issues At Advisory Cmte
Aerie's Netarsudil's Safety Questions May Determine Fate At Advisory Committee
Historical Control In Psoriatic Arthritis May Hinge On Background Therapy
Could FDA Force Pfizer To Push Shingles Vaccination With Xeljanz Psoriatic Arthritis Approval?
Pfizer's Xeljanz Gains FDA Panel Nod In Psoriatic Arthritis, But Labeling Questions Remain





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts